Multiple Sclerosis
Conditions
Keywords
Spinal cord, Spinal cord atrophy, Cerebrospinal Fluid, Swiss Multiple Sclerosis Cohort
Brief summary
Research project in which patients with Multiple Sclerosis (MS) are examined clinically and with magnetic resonance imaging (MRI). To evaluate spinal cord (SC) grey and white matter changes (incl. lesions) using fast, high-resolution MRI sequences with high contrast between SC and cerebrospinal fluid (CSF) as well as high contrast within the SC (grey-white matter contrast).
Detailed description
The Swiss Multiple Sclerosis Cohort (SMSC-Study) aims to better evaluate specific Multiple Sclerosis (MS) phenotypes through the systematic and standardised documentation and acquisition of clinical course and paraclinical tests such as magnetic resonance imaging (MRI), blood and cerebrospinal fluid (CSF) specimens. Determination of the relative contribution of SC metrics (cervical cord volume, cervical grey matter (GM) cord volume, cervical white matter (WM) cord volume, SC lesion load) to disability in MS.
Interventions
DIAGNOSTIC_TESTspinal cord MRI
high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of multiple sclerosis * Steroid free period: \> 4 weeks * healthy controls without any history of severe neurological, internistic or psychiatric disease
Exclusion criteria
for all participants: * History of severe (other) neurological, internistic or psychiatric disease * MRI related
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in SC atrophy assessed by MRI | at baseline and after 1 year | Determination of the degree of SC grey and white matter atrophy in MS patients with relapsing versus progressive disease courses in comparison to matched HC. Measurement tool is a structural MRI of the brain and spinal cord at 3 Tesla. Assessment will last approx. 90 minutes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Timed 25-foot walk test (T25-FW) | at baseline and after 1 year and after 5 years | Quantitative mobility and leg function performance test ( in MS patients) based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. |
| Change in Multiple Sclerosis Walking Scale-12 (MSWS-12) Questionnaire | at baseline and after 1 year and after 5 years | Self-assessment scale which measures the impact of MS on walking. It consists of 12 questions concerning the limitations to walking due to MS during the past 2 weeks. Each item can be answered with 5 options, with 1 meaning no limitation and 5 extreme limitation. |
Countries
Switzerland
Outcome results
None listed